Back to all available

Integrative metabolomics-GWAS mendelian randomization reveals causal metabolic and inflammatory drivers of parkinson’s disease

geriatrics
neurology
metabolic-sciences

Abstract

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by a complex pathogenesis involving the interplay of multiple molecular and cellular pathways. In recent years, metabolic dysregulation and neuroinflammation have been recognized as key contributors to PD onset and progression, potentially mediating neurodegenerative changes by affecting dopaminergic neuron survival, synaptic function, and neural network homeostasis. However, conventional observational studies are limited in establishing causal relationships between these metabolites and inflammatory mediators, highlighting the urgent need for systematic identification using genetic approaches.
Meathods : Using Mendelian randomization, this study systematically elucidates, for the first time, the causal roles of key metabolites and inflammatory mediators in PD. These findings provide critical genetic evidence for the identification of early biomarkers and the development of potential therapeutic targets, while also offering novel insights into the mechanistic interplay between metabolic dysregulation and inflammation in neurodegenerative diseases.
Result: A total of 722 differential metabolites were identified, of which three had corresponding genetic information in GWAS datasets. In addition, 14 caffeine-related metabolites and 91 inflammatory mediators were included in the MR analysis. The results showed that 1-Methylnicotinamide, Flt3L, IL-13, and ST1A1 were negatively associated with PD, suggesting potential protective effects, whereas FGF-5, IL-4, and CCL13 exhibited positive causal associations, indicating potential risk-promoting roles. These findings highlight the central role of inflammatory pathways in PD pathogenesis and progression and suggest a potential interplay between metabolic dysregulation and inflammatory responses.
Conclusion: This study, using Mendelian randomization, systematically elucidates for the first time the causal roles of key metabolites and inflammatory mediators in PD, providing critical theoretical evidence for the identification of early biomarkers and the development of potential therapeutic targets, while also offering novel genetic insights into the mechanistic interplay between metabolic dysregulation and inflammation in neurodegenerative diseases.
Ask to review this manuscript

Notes for potential reviewers

  • Volunteering is not a guarantee that you will be asked to review. There are many reasons: reviewers must be qualified, there should be no conflicts of interest, a minimum of two reviewers have already accepted an invitation, etc.
  • This is NOT OPEN peer review. The review is single-blind, and all recommendations are sent privately to the Academic Editor handling the manuscript. All reviews are published and reviewers can choose to sign their reviews.
  • What happens after volunteering? It may be a few days before you receive an invitation to review with further instructions. You will need to accept the invitation to then become an official referee for the manuscript. If you do not receive an invitation it is for one of many possible reasons as noted above.
  • PeerJ does not judge submissions based on subjective measures such as novelty, impact or degree of advance. Effectively, reviewers are asked to comment on whether or not the submission is scientifically and technically sound and therefore deserves to join the scientific literature. Our Peer Review criteria can be found on the "Editorial Criteria" page - reviewers are specifically asked to comment on 3 broad areas: "Basic Reporting", "Experimental Design" and "Validity of the Findings".
  • Reviewers are expected to comment in a timely, professional, and constructive manner.
  • Until the article is published, reviewers must regard all information relating to the submission as strictly confidential.
  • When submitting a review, reviewers are given the option to "sign" their review (i.e. to associate their name with their comments). Otherwise, all review comments remain anonymous.
  • All reviews of published articles are published. This includes manuscript files, peer review comments, author rebuttals and revised materials.
  • Each time a decision is made by the Academic Editor, each reviewer will receive a copy of the Decision Letter (which will include the comments of all reviewers).

If you have any questions about submitting your review, please email us at [email protected].